Cytomegalovirus vaccine in renal transplant candidates: Progress report of a randomized, placebo-controlled, double-blind trial

H. H. Balfour, G. W. Sachs, P. Welo, R. C. Gehrz, R. L. Simmons, J. S. Najarian

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Prospective studies now have confirmed that CMV is an important pathogen for renal allograft recipients. Investigations from at least 12 renal transplant centers have provided convincing evidence that CMV is a major posttransplant problem, causing fever, leukopenia, arthralgia, pneumonitis, hepatitis, GI bleeding, encephalitis, retinitis, graft loss, and mortality. In our prospective study of 272 renal allograft recipients, CMV infection occurred after 181 (57%) transplants. Using a multivariate analysis that employed an exponential survival model, CMV was significant risk factor (P <0.05) for posttransplant fever, leukopenia, graft failure, and mortality.

Original languageEnglish (US)
Pages (from-to)289-304
Number of pages16
JournalBirth Defects: Original Article Series
Volume20
Issue number1
StatePublished - Dec 1 1984

Fingerprint Dive into the research topics of 'Cytomegalovirus vaccine in renal transplant candidates: Progress report of a randomized, placebo-controlled, double-blind trial'. Together they form a unique fingerprint.

  • Cite this